Inside the push to get weight loss treatment covered by Medicare Reuters reported that the medications, which fall into the GLP-1 agonist class of drugs, have been shown to help reduce a person ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

So far, benefits associated with consistent GLP-1 use in curbing medical spending lack sufficient data-backed evidence. It’s ...

The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

More medicines will be spared from Medicare price negotiations, a change that is projected to wipe out billions in savings ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Medicare Part D covers Ozempic, but the drug is not prescribed solely for weight loss. Patients using the drug for that purpose would have to pay for the injections out of pocket. Novo Nordisk’s ...